AlzeCure Pharma Today Presented Key Preclinical Data on its Novel Cognitive Enhancer at the AAT-AD/PD Conference - Seite 3

About Alzheimer's disease

Alzheimer's disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on families and on the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute.The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than 10 billion USD in yearly sales. In Sweden, approximately 100 000 persons suffer from Alzheimer's disease with a healthcare cost of about 63 billion SEK yearly, which is more than for cancer and cardiovascular diseases combined.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/alzecure-pharma-ab/r/alzecure-pharma-today-presented-key-preclinical-data-on-its-novel-cognitive-enhancer-at-the-aat-ad-p,c3079512

The following files are available for download:

https://mb.cision.com/Main/16466/3079512/1222983.pdf	Release
https://news.cision.com/alzecure-pharma-ab/i/alzecure-logo,c2768622	AlzeCure logo
https://news.cision.com/alzecure-pharma-ab/i/brain,c2768623	Brain
https://news.cision.com/alzecure-pharma-ab/i/dr--pontus-forsell,c27686 ...	Dr. Pontus Forsell
https://news.cision.com/alzecure-pharma-ab/i/professor-bengt-winblad,c ...	Professor Bengt Winblad